Report cover image

Constrained Peptide Drugs Market, By Peptide Type, By Therapeutic Area, By Synthesis Method, By Route of Administration, By End User, By Country, and By Region – Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032

Publisher AnalystView Market Insights
Published Jun 04, 2025
Length 316 Pages
SKU # ANVM20865209

Description

REPORT HIGHLIGHT

Constrained peptide drugs market size was valued at US$ 1,560.32 Million in 2024, expanding at a CAGR of 16.20% from 2025 to 2032.

Constrained peptide drugs are specially designed molecules where the peptide’s structure is chemically “locked” into a stable shape. This constraint improves their stability, enhances binding to specific targets, and increases resistance to degradation by enzymes in the body. These features make them highly effective in treating diseases by precisely interacting with biological molecules, offering advantages over traditional peptides such as improved potency, selectivity, and longer-lasting therapeutic effects.

Constrained Peptide Drugs Market- Market Dynamics

Increasing prevalence of chronic diseases to propel market demand
The rising prevalence of chronic diseases is driving the growth of the global constrained peptide drugs market. According to the CDC, approximately 6 in 10 adults in the U.S. have a chronic disease, driving demand for targeted therapies like constrained peptide drugs. Besides, advancements in peptide stabilization is another factor projected to boost the market growth. However, high production costs and regulatory challenges is expected to hamper the market growth in the coming years. On the contrary, expanding applications in oncology and increasing investment in personalized, providing opportunities for peptide drugs designed for individual patient profiles.

Constrained Peptide Drugs Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 16.20% over the forecast period (2025-2032)
Based on Peptide Type segmentation, cyclized peptides was predicted to show maximum market share in the year 2024
Based on Therapeutic Area segmentation, oncology was the leading Therapeutic Area in 2024
Based on Synthesis Method segmentation, solid phase peptide synthesis was the leading Synthesis Method in 2024
Based on Route of Administration segmentation, subcutaneous was the leading Route of Administration in 2024
Based on end user segmentation, Hospital was the leading end user in 2024
On the basis of region, North America was the leading revenue generator in 2024

Constrained Peptide Drugs Market- Segmentation Analysis:

The Global Constrained Peptide Drugs Market is segmented on the basis of Peptide Type, Therapeutic Area, Synthesis Method, Route of Administration, End User, and Region.
The market is divided into four categories based on Peptide Type: cyclized peptides, macrocyclic peptides, D-peptides, and stapled peptides. The cyclized peptides segment is expected to hold the major market share during the forecast period, driven by their enhanced stability, improved bioavailability, and widespread applications in therapeutic areas compared to other peptide types.
The market is divided into two categories based on Therapeutic Area: infectious diseases, cardiovascular diseases, Cns Disorders, oncology, and metabollic disorders. The oncology segment is expected to hold the major market share in the global constrained peptide drugs market, due to increasing cancer prevalence and the effectiveness of peptide drugs in targeted cancer therapies.

Constrained Peptide Drugs Market- Geographical Insights

The North America region is expected to hold the major constrained peptide drugs market share during the forecast period, driven by advanced healthcare infrastructure, increased R&D investments, and high adoption of innovative therapies. Meanwhile, the Asia-Pacific region is projected to grow at the fastest rate due to rising healthcare awareness, expanding patient populations, and growing investments in biotechnology and pharmaceutical sectors across emerging economies.

Constrained Peptide Drugs Market- Competitive Landscape:

Rising demand for targeted and stable therapeutics drives innovation in constrained peptide drugs. Companies focus on advancing peptide stabilization technologies and enhancing delivery methods to improve efficacy and patient compliance. Strategic partnerships and collaborations with research institutes accelerate drug development and expand product pipelines. Additionally, investments in expanding manufacturing capabilities and penetrating emerging markets help capitalize on growing healthcare needs. Emphasis on personalized medicine and novel peptide formats further strengthens competitive positioning in this evolving landscape.

Recent Developments:

In January 2025, Bicycle Therapeutics plc shared updated Phase 1 combination results for zelenectide pevedotin with pembrolizumab in cisplatin-ineligible metastatic urothelial cancer patients, along with key accomplishments and strategic plans for 2025.

SCOPE OF THE REPORT


The scope of this report covers the market by its major segments, which include as follows:

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

Amgen Inc.
Pfizer Inc.
Novartis AG
Merck & Co., Inc.
F. Hoffmann-La Roche Ltd.
Sanofi S.A.
Bicycle Therapeutics PLC
Bristol-Myers Squibb Company
Aileron Therapeutics, Inc.
Eli Lilly and Company
Aileron Therapeutics Inc.
Spexis AG
Santhera Pharmaceuticals
Protagonist Therapeutics Inc.
Union Chimique Belge S.A. (UCB)
Biosynth (Pepscan)
Creative Peptides
Pepticom Ltd.
Bio-Synthesis Inc.
PeptiDream Inc.
CPC Scientific Inc.
Chugai Pharmaceutical Co. Ltd.
Circle Pharma
Others

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY PEPTIDE TYPE- MARKET ANALYSIS, 2019 - 2032

Cyclized Peptides
Macrocyclic Peptides
D-Peptides
Stapled Peptides

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

Infectious Diseases
Cardiovascular Diseases
Cns Disorders
Oncology
Metabollic Disorders

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY SYNTHESIS METHOD- MARKET ANALYSIS, 2019 - 2032

Solid Phase Peptide Synthesis
Recombinant Technology

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

Oral
Intravenous
Transdermal
Subcutaneous

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

Hospitals
Research Institutes
Pharmaceutical Companies

GLOBAL CONSTRAINED PEPTIDE DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
The Netherlands
Sweden
Russia
Poland
Rest of Europe
Asia Pacific
China
India
Japan
South Korea
Australia
Indonesia
Thailand
Philippines
Rest of APAC
Latin America
Brazil
Mexico
Argentina
Colombia
Rest of LATAM
The Middle East and Africa
Saudi Arabia
UAE
Israel
Turkey
Algeria
Egypt
Rest of MEA

Table of Contents

316 Pages
1. Constrained Peptide Drugs Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. Constrained Peptide Drugs Market Snippet by Peptide Type
2.1.2. Constrained Peptide Drugs Market Snippet by Therapeutic Area
2.1.3. Constrained Peptide Drugs Market Snippet by Synthesis Method
2.1.4. Constrained Peptide Drugs Market Snippet by Route of Administration
2.1.5. Constrained Peptide Drugs Market Snippet by End User
2.1.6. Constrained Peptide Drugs Market Snippet by Country
2.1.7. Constrained Peptide Drugs Market Snippet by Region
2.2. Competitive Insights
3. Constrained Peptide Drugs Key Market Trends
3.1. Constrained Peptide Drugs Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. Constrained Peptide Drugs Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. Constrained Peptide Drugs Market Opportunities
3.4. Constrained Peptide Drugs Market Future Trends
4. Constrained Peptide Drugs Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. Constrained Peptide Drugs Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. Constrained Peptide Drugs Market Landscape
6.1. Constrained Peptide Drugs Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. Constrained Peptide Drugs Market – By Peptide Type
7.1. Overview
7.1.1. Segment Share Analysis, By Peptide Type, 2024 & 2032 (%)
7.1.2. Cyclized Peptides
7.1.3. Macrocyclic Peptides
7.1.4. D-Peptides
7.1.5. Stapled Peptides
8. Constrained Peptide Drugs Market – By Therapeutic Area
8.1. Overview
8.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
8.1.2. Infectious Diseases
8.1.3. Cardiovascular Diseases
8.1.4. Cns Disorders
8.1.5. Oncology
8.1.6. Metabollic Disorders
9. Constrained Peptide Drugs Market – By Synthesis Method
9.1. Overview
9.1.1. Segment Share Analysis, By Synthesis Method, 2024 & 2032 (%)
9.1.2. Solid Phase Peptide Synthesis
9.1.3. Recombinant Technology
10. Constrained Peptide Drugs Market – By Route of Administration
10.1. Overview
10.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
10.1.2. Oral
10.1.3. Intravenous
10.1.4. Transdermal
10.1.5. Subcutaneous
11. Constrained Peptide Drugs Market – By End User
11.1. Overview
11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
11.1.2. Hospitals
11.1.3. Research Institutes
11.1.4. Pharmaceutical Companies
12. Constrained Peptide Drugs Market– By Geography
12.1. Introduction
12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
12.2. North America
12.2.1. Overview
12.2.2. Constrained Peptide Drugs Key Manufacturers in North America
12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.2.4. North America Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.2.5. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.2.6. North America Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.2.7. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.9. U.S.
12.2.9.1. Overview
12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.9.3. U.S. Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.2.9.4. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.2.9.5. U.S. Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.2.9.6. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.2.10. Canada
12.2.10.1. Overview
12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.2.10.3. Canada Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.2.10.4. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.2.10.5. Canada Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.2.10.6. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3. Europe
12.3.1. Overview
12.3.2. Constrained Peptide Drugs Key Manufacturers in Europe
12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.3.4. Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.5. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.6. Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.7. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.9. Germany
12.3.9.1. Overview
12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.9.3. Germany Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.9.4. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.9.5. Germany Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.9.6. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.10. UK
12.3.10.1. Overview
12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.10.3. UK Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.10.4. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.10.5. UK Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.10.6. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.11. France
12.3.11.1. Overview
12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.11.3. France Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.11.4. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.11.5. France Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.11.6. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.12. Italy
12.3.12.1. Overview
12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.12.3. Italy Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.12.4. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.12.5. Italy Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.12.6. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.13. Spain
12.3.13.1. Overview
12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.13.3. Spain Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.13.4. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.13.5. Spain Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.13.6. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.14. The Netherlands
12.3.14.1. Overview
12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.14.3. The Netherlands Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.14.4. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.14.5. The Netherlands Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.14.6. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.15. Sweden
12.3.15.1. Overview
12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.15.3. Sweden Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.15.4. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.15.5. Sweden Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.15.6. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.16. Russia
12.3.16.1. Overview
12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.16.3. Russia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.16.4. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.16.5. Russia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.16.6. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.17. Poland
12.3.17.1. Overview
12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.17.3. Poland Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.17.4. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.17.5. Poland Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.17.6. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.3.18. Rest of Europe
12.3.18.1. Overview
12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.3.18.3. Rest of the Europe Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.3.18.4. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.3.18.5. Rest of the Europe Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.3.18.6. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4. Asia Pacific (APAC)
12.4.1. Overview
12.4.2. Constrained Peptide Drugs Key Manufacturers in Asia Pacific
12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.4.4. APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.5. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.6. APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.7. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.9. China
12.4.9.1. Overview
12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.9.3. China Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.9.4. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.9.5. China Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.9.6. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.10. India
12.4.10.1. Overview
12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.10.3. India Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.10.4. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.10.5. India Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.10.6. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.11. Japan
12.4.11.1. Overview
12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.11.3. Japan Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.11.4. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.11.5. Japan Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.11.6. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.12. South Korea
12.4.12.1. Overview
12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.12.3. South Korea Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.12.4. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.12.5. South Korea Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.12.6. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.13. Australia
12.4.13.1. Overview
12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.13.3. Australia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.13.4. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.13.5. Australia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.13.6. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.14. Indonesia
12.4.14.1. Overview
12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.14.3. Indonesia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.14.4. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.14.5. Indonesia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.14.6. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.15. Thailand
12.4.15.1. Overview
12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.15.3. Thailand Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.15.4. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.15.5. Thailand Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.15.6. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.16. Philippines
12.4.16.1. Overview
12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.16.3. Philippines Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.16.4. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.16.5. Philippines Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.16.6. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.4.17. Rest of APAC
12.4.17.1. Overview
12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.4.17.3. Rest of APAC Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.4.17.4. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.4.17.5. Rest of APAC Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.4.17.6. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5. Latin America (LATAM)
12.5.1. Overview
12.5.2. Constrained Peptide Drugs Key Manufacturers in Latin America
12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.5.4. LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.5. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.6. LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.7. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.9. Brazil
12.5.9.1. Overview
12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.9.3. Brazil Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.9.4. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.9.5. Brazil Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.9.6. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.10. Mexico
12.5.10.1. Overview
12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.10.3. Mexico Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.10.4. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.10.5. Mexico Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.10.6. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.11. Argentina
12.5.11.1. Overview
12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.11.3. Argentina Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.11.4. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.11.5. Argentina Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.11.6. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.12. Colombia
12.5.12.1. Overview
12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.12.3. Colombia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.12.4. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.12.5. Colombia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.12.6. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.5.13. Rest of LATAM
12.5.13.1. Overview
12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.5.13.3. Rest of LATAM Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.5.13.4. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.5.13.5. Rest of LATAM Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.5.13.6. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6. Middle East and Africa
12.6.1. Overview
12.6.2. Constrained Peptide Drugs Key Manufacturers in Middle East and Africa
12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
12.6.4. Middle East and Africa Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.5. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.6. Middle East and Africa Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.7. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.9. Saudi Arabia
12.6.9.1. Overview
12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.9.3. Saudi Arabia Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.9.4. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.9.5. Saudi Arabia Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.9.6. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.10. United Arab Emirates
12.6.10.1. Overview
12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.10.3. United Arab Emirates Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.10.4. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.10.5. United Arab Emirates Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.10.6. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.11. Israel
12.6.11.1. Overview
12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.11.3. Israel Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.11.4. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.11.5. Israel Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.11.6. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.12. Turkey
12.6.12.1. Overview
12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.12.3. Turkey Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.12.4. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.12.5. Turkey Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.12.6. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.13. Algeria
12.6.13.1. Overview
12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.13.3. Algeria Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.13.4. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.13.5. Algeria Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.13.6. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.14. Egypt
12.6.14.1. Overview
12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.14.3. Egypt Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.14.4. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.14.5. Egypt Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.14.6. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12.6.15. Rest of MEA
12.6.15.1. Overview
12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
12.6.15.3. Rest of MEA Market Size and Forecast, By Peptide Type, 2019 - 2032 (US$ Million)
12.6.15.4. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
12.6.15.5. Rest of MEA Market Size and Forecast, By Synthesis Method, 2019 - 2032 (US$ Million)
12.6.15.6. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
13. Key Vendor Analysis- Constrained Peptide Drugs Industry
13.1. Competitive Dashboard
13.1.1. Competitive Benchmarking
13.1.2. Competitive Positioning
13.2. Company Profiles
13.2.1. Amgen Inc.
13.2.2. Pfizer Inc.
13.2.3. Novartis AG
13.2.4. Merck & Co., Inc.
13.2.5. F. Hoffmann-La Roche Ltd.
13.2.6. Sanofi S.A.
13.2.7. Bicycle Therapeutics PLC
13.2.8. Bristol-Myers Squibb Company
13.2.9. Aileron Therapeutics, Inc.
13.2.10. Eli Lilly and Company
13.2.11. Aileron Therapeutics Inc.
13.2.12. Spexis AG
13.2.13. Santhera Pharmaceuticals
13.2.14. Protagonist Therapeutics Inc.
13.2.15. Union Chimique Belge S.A. (UCB)
13.2.16. Biosynth (Pepscan)
13.2.17. Creative Peptides
13.2.18. Pepticom Ltd.
13.2.19. Bio-Synthesis Inc.
13.2.20. PeptiDream Inc.
13.2.21. CPC Scientific Inc.
13.2.22. Chugai Pharmaceutical Co. Ltd.
13.2.23. Circle Pharma
13.2.24. Others
14. 360 Degree Analyst View
15. Appendix
15.1. Research Methodology
15.2. References
15.3. Abbreviations
15.4. Disclaimer
15.5. Contact Us

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us